stoxline Quote Chart Rank Option Currency Glossary
  
Neumora Therapeutics, Inc. Common Stock (NMRA)
1.74  0.05 (2.96%)    02-14 16:00
Open: 1.72
High: 1.795
Volume: 1,190,581
  
Pre. Close: 1.69
Low: 1.7
Market Cap: 281(M)
Technical analysis
2025-02-14 4:50:07 PM
Short term     
Mid term     
Targets 6-month :  2.47 1-year :  2.84
Resists First :  2.11 Second :  2.44
Pivot price 1.86
Supports First :  1.6 Second :  1.33
MAs MA(5) :  1.71 MA(20) :  1.91
MA(100) :  9.05 MA(250) :  10.81
MACD MACD :  -1 Signal :  -1.2
%K %D K(14,3) :  18.9 D(3) :  13.9
RSI RSI(14): 23
52-week High :  21 Low :  1.6
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ NMRA ] has closed above bottom band by 22.8%. Bollinger Bands are 90.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 1.8 - 1.81 1.81 - 1.82
Low: 1.68 - 1.69 1.69 - 1.7
Close: 1.72 - 1.74 1.74 - 1.76
Company Description

Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.

Headline News

Sat, 15 Feb 2025
NMRA INVESTOR NOTICE: Neumora Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - PR Newswire

Fri, 14 Feb 2025
Lowey Dannenberg Notifies Neumora Therapeutics, Inc. - GlobeNewswire

Fri, 14 Feb 2025
NMRA Investor Alert: A Securities Fraud Class Action Lawsuit Has Been Filed Against Neumora Therapeutics, Inc. (NMRA) - Contact Kessler Topaz Meltzer & Check, LLP - PR Newswire

Fri, 14 Feb 2025
Neumora Therapeutics, Inc. Class Action Alert: Wolf Haldenstein Adler Freeman & Herz LLP reminds investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Neumora Therape - Morningstar

Thu, 13 Feb 2025
Neumora Therapeutics, Inc. Shareholder Notice: Shareholder - GlobeNewswire

Thu, 13 Feb 2025
Class Action Filed Against Neumora Therapeutics, Inc. (NMRA) Seeking Recovery for Investors - Contact The Gross Law Firm - Morningstar

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 162 (M)
Shares Float 83 (M)
Held by Insiders 27.4 (%)
Held by Institutions 66.3 (%)
Shares Short 11,030 (K)
Shares Short P.Month 10,830 (K)
Stock Financials
EPS -1.21
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 2.38
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -1.55
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio -1.45
PEG Ratio 0
Price to Book value 0.73
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android